Cargando…

Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation

BACKGROUND: Pimobendan has been proven to delay the onset of congestive heart failure (CHF) in dogs with mitral regurgitation (MR); however, molecular underlying mechanisms have not been fully elucidated. This study aimed to investigate (1) the effects of pimobendan on cardiac function, cardiac mito...

Descripción completa

Detalles Bibliográficos
Autores principales: Boonpala, Pakit, Saengklub, Nakkawee, Srikam, Sirinapa, Ji-au, Wilawan, Panyasing, Yaowalak, Kumphune, Sarawut, Kijtawornrat, Anusak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463781/
https://www.ncbi.nlm.nih.gov/pubmed/37612694
http://dx.doi.org/10.1186/s12917-023-03693-2
_version_ 1785098312281489408
author Boonpala, Pakit
Saengklub, Nakkawee
Srikam, Sirinapa
Ji-au, Wilawan
Panyasing, Yaowalak
Kumphune, Sarawut
Kijtawornrat, Anusak
author_facet Boonpala, Pakit
Saengklub, Nakkawee
Srikam, Sirinapa
Ji-au, Wilawan
Panyasing, Yaowalak
Kumphune, Sarawut
Kijtawornrat, Anusak
author_sort Boonpala, Pakit
collection PubMed
description BACKGROUND: Pimobendan has been proven to delay the onset of congestive heart failure (CHF) in dogs with mitral regurgitation (MR); however, molecular underlying mechanisms have not been fully elucidated. This study aimed to investigate (1) the effects of pimobendan on cardiac function, cardiac mitochondrial quality and morphology, and cardiac ultrastructure in a rat model of chronic MR and (2) the direct effect of pimobendan on intracellular reactive oxygen species (ROS) production in cardiac cells. MR was surgically induced in 20 Sprague-Dawley rats, and sham procedures were performed on 10 rats. Eight weeks post-surgery, the MR rats were randomly divided into two groups: the MR group and the MR + pimobendan group. Pimobendan (0.15 mg/kg) was administered twice a day via oral gavage for 4 weeks, whereas the sham and MR groups received equivalent volumes of drinking water. Echocardiography was performed at baseline (8 weeks post-surgery) and at the end of the study (4 weeks after treatment). At the end of the study protocol, all rats were euthanized, and their hearts were immediately collected, weighed, and used for transmission electron microscopy and mitochondrial quality assessments. To evaluate the role of pimobendan on intracellular ROS production, preventive or scavenging properties were tested with H(2)O(2)-induced ROS generation in rat cardiac myoblasts (H9c2). RESULTS: Pimobendan preserved cardiac functions and structure in MR rats. In addition, pimobendan significantly improved mitochondrial quality by attenuating ROS production and depolarization (P < 0.05). The cardiac ultrastructure and mitochondrial morphology were significantly preserved in the MR + pimobendan group. In addition, pimobendan appeared to play as a ROS scavenger, but not as a ROS preventer, in H(2)O(2)-induced ROS production in H9c2 cells. CONCLUSIONS: Pimobendan demonstrated cardioprotective effects on cardiac function and ultrastructure by preserving mitochondrial quality and acted as an ROS scavenger in a rat model of MR. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12917-023-03693-2.
format Online
Article
Text
id pubmed-10463781
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104637812023-08-30 Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation Boonpala, Pakit Saengklub, Nakkawee Srikam, Sirinapa Ji-au, Wilawan Panyasing, Yaowalak Kumphune, Sarawut Kijtawornrat, Anusak BMC Vet Res Research BACKGROUND: Pimobendan has been proven to delay the onset of congestive heart failure (CHF) in dogs with mitral regurgitation (MR); however, molecular underlying mechanisms have not been fully elucidated. This study aimed to investigate (1) the effects of pimobendan on cardiac function, cardiac mitochondrial quality and morphology, and cardiac ultrastructure in a rat model of chronic MR and (2) the direct effect of pimobendan on intracellular reactive oxygen species (ROS) production in cardiac cells. MR was surgically induced in 20 Sprague-Dawley rats, and sham procedures were performed on 10 rats. Eight weeks post-surgery, the MR rats were randomly divided into two groups: the MR group and the MR + pimobendan group. Pimobendan (0.15 mg/kg) was administered twice a day via oral gavage for 4 weeks, whereas the sham and MR groups received equivalent volumes of drinking water. Echocardiography was performed at baseline (8 weeks post-surgery) and at the end of the study (4 weeks after treatment). At the end of the study protocol, all rats were euthanized, and their hearts were immediately collected, weighed, and used for transmission electron microscopy and mitochondrial quality assessments. To evaluate the role of pimobendan on intracellular ROS production, preventive or scavenging properties were tested with H(2)O(2)-induced ROS generation in rat cardiac myoblasts (H9c2). RESULTS: Pimobendan preserved cardiac functions and structure in MR rats. In addition, pimobendan significantly improved mitochondrial quality by attenuating ROS production and depolarization (P < 0.05). The cardiac ultrastructure and mitochondrial morphology were significantly preserved in the MR + pimobendan group. In addition, pimobendan appeared to play as a ROS scavenger, but not as a ROS preventer, in H(2)O(2)-induced ROS production in H9c2 cells. CONCLUSIONS: Pimobendan demonstrated cardioprotective effects on cardiac function and ultrastructure by preserving mitochondrial quality and acted as an ROS scavenger in a rat model of MR. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12917-023-03693-2. BioMed Central 2023-08-23 /pmc/articles/PMC10463781/ /pubmed/37612694 http://dx.doi.org/10.1186/s12917-023-03693-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Boonpala, Pakit
Saengklub, Nakkawee
Srikam, Sirinapa
Ji-au, Wilawan
Panyasing, Yaowalak
Kumphune, Sarawut
Kijtawornrat, Anusak
Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation
title Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation
title_full Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation
title_fullStr Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation
title_full_unstemmed Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation
title_short Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation
title_sort pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463781/
https://www.ncbi.nlm.nih.gov/pubmed/37612694
http://dx.doi.org/10.1186/s12917-023-03693-2
work_keys_str_mv AT boonpalapakit pimobendanpreventscardiacdysfunctionmitigatescardiacmitochondrialdysfunctionandpreservesmyocyteultrastructureinaratmodelofmitralregurgitation
AT saengklubnakkawee pimobendanpreventscardiacdysfunctionmitigatescardiacmitochondrialdysfunctionandpreservesmyocyteultrastructureinaratmodelofmitralregurgitation
AT srikamsirinapa pimobendanpreventscardiacdysfunctionmitigatescardiacmitochondrialdysfunctionandpreservesmyocyteultrastructureinaratmodelofmitralregurgitation
AT jiauwilawan pimobendanpreventscardiacdysfunctionmitigatescardiacmitochondrialdysfunctionandpreservesmyocyteultrastructureinaratmodelofmitralregurgitation
AT panyasingyaowalak pimobendanpreventscardiacdysfunctionmitigatescardiacmitochondrialdysfunctionandpreservesmyocyteultrastructureinaratmodelofmitralregurgitation
AT kumphunesarawut pimobendanpreventscardiacdysfunctionmitigatescardiacmitochondrialdysfunctionandpreservesmyocyteultrastructureinaratmodelofmitralregurgitation
AT kijtawornratanusak pimobendanpreventscardiacdysfunctionmitigatescardiacmitochondrialdysfunctionandpreservesmyocyteultrastructureinaratmodelofmitralregurgitation